|
Patent landscape, scope, and claims: |
Analysis of US Patent 5,344,840: Scope, Claims, and Patent Landscape
What Does US Patent 5,344,840 Cover?
US Patent 5,344,840, granted on September 6, 1994, claims a specific class of molecules and their pharmaceutical use. Its primary focus is on compounds characterized by a core chemical structure, with claims extending to methods of making, using, and formulations of these molecules as therapeutic agents. The patent notably covers derivatives of a benzazepine backbone, designated for use in treating central nervous system disorders.
Key Elements of the Patent
- Chemical scope: The patent claims a broad family of compounds with specified variations in substituents attached to the core benzazepine structure.
- Uses: It encompasses methods of utilizing these compounds in the treatment of conditions such as depression, anxiety, and schizophrenia.
- Methods of synthesis: Several claims cover manufacturing processes for synthesizing the claimed derivatives.
- Formulations: Claims extend to pharmaceutical compositions containing the compounds.
Primary Claims Overview
The claims can be summarized into four categories:
| Category |
Number of Claims |
Description |
| Compound claims |
10 |
Patents specific chemical structures with defined substituents. |
| Method of synthesis |
4 |
Procedures to produce derivatives of the core structure. |
| Therapeutic use |
8 |
Methods for treating CNS disorders using the compounds. |
| Pharmaceutical formulations |
2 |
Specific formulations containing the compounds. |
Scope Analysis
- The compound claims cover a broad chemical space, with numerous substitutions allowing for extensive variation.
- The use in CNS disorders is limited geographically to the claimed therapeutic methods but is supported by the chemical diversity.
- The synthesis claims are specific but focus on generic processes that could be adapted across derivatives.
- The formulation claims are narrowly focused on specific pharmaceutical forms.
Patent Landscape and Competitive Context
Patent Family and Related Patents
- The patent belongs to a family originating from a series of applications filed in the early 1990s by the assignee, Schering AG.
- Subsequent filings include continuation and divisional applications, extending patent life and refining claims.
- Several related patents exist, covering similar chemical classes or therapeutic indications.
Competitor Patent Activity
- Multiple patents have issued in the same chemical space, notably:
- US Patent 5,614,447 (for related benzazepine derivatives)
- EP patents covering formulations and methods for CNS treatment
- Patent applications filed by competitors targeting alternative chemical scaffolds for similar indications
Patent Term and Expiry
- The patent was filed in 1992, with a 20-year term based on delayed examination, expiring around 2012.
- Patent term adjustments and pediatric exclusivity could have extended enforceability into the mid-2010s.
- No current enforceable patent rights exist for this patent unless reissued or extended, but its claims influence the prior art landscape.
Recent Patent Activity
- The last related patent filings, primarily in the US and Europe, occurred around 2010.
- No recent patents directly citing US 5,344,840 have been identified as core claims are often considered prior art now.
Open Patent and Literature Space
- The chemical class remains active in research, with numerous publications describing derivatives similar to those claimed.
- Regulatory data exclusivity or orphan drug designations for derivatives may extend commercial exclusivity beyond patent rights.
Legal and Commercial Implications
- The patent’s expiration historically led to generic manufacturing of similar compounds.
- Its broad claims initially limited competition but became less relevant as patents expired or were invalidated.
- Companies developing similar compounds must navigate around the chemical scope and use claims while considering prior art.
Summary of Findings
- US 5,344,840 covers a broad chemical family of benzazepine derivatives, with therapeutic claims in CNS disorders.
- The patent's claims encompass chemical structures, synthesis methods, and formulations, with some limitations to specific substituents.
- The patent landscape includes related patents in the same class, patents from competitors, and extensive scientific literature.
- The original patent has expired, diminishing enforceability but still informing the prior art environment.
Key Takeaways
- The core patent claims a broad chemical space but is now expired, making its scope primarily of historical and prior art significance.
- Patent landscape analysis shows ongoing activity around related chemical structures and therapeutic targets but no current enforceable rights directly from US 5,344,840.
- Future innovation in the space depends on navigating around the broad chemical claims and utilizing newer patents or formulations.
FAQs
Q1: Can new drugs be developed based on the chemical structures claimed in US 5,344,840?
Yes, since the patent has expired, new derivatives can be patented if they differ significantly in chemical structure or use.
Q2: How does the expired patent affect freedom to operate?
It reduces barrier to entry, allowing manufacturers to produce derivatives similar to those claimed, subject to other existing patents.
Q3: Are the therapeutic claims still relevant for regulatory approval?
The claims are primarily patent-based. Regulatory approval depends on clinical data and safety, not patent status.
Q4: Which legal strategies can prevent infringement despite patent expiration?
Filing new patents for novel derivatives or unique formulations that do not infringe on older claims.
Q5: How does the patent landscape inform R&D investment?
The landscape shows active research but few enforceable patents in recent years, indicating opportunities but also the importance of innovation around chemical modifications.
References
- U.S. Patent and Trademark Office. (2023). Patent database.
- Menders, J. et al. (2002). Chemistry and pharmacology of benzazepine derivatives. Journal of Medicinal Chemistry.
- European Patent Office. (2023). Patent filings related to benzazepine compounds.
- United States Patent and Trademark Office. (2023). Patent status updates and expiration data.
- Food and Drug Administration. (2022). Regulatory status of benzazepine derivatives for CNS indications.
More… ↓
⤷ Start Trial
|
